| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig 1a
| Gabanti E, Bruno F, Scaramuzzi L, Mangione F, Zelini P, Gerna G, et al. Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli. New Microbiol. 2016;39:247-258 pubmed |
- immunocytochemistry; human; fig 1
| Chacon J, Sarnaik A, Chen J, Creasy C, Kale C, Robinson J, et al. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21:611-21 pubmed publisher |
| Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher |
| Adamo S, Gao Y, Sekine T, Mily A, Wu J, Storg xe4 rd E, et al. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell Host Microbe. 2023;31:928-936.e4 pubmed publisher |
| Lao L, Zeng W, Huang P, Chen H, Jia Z, Wang P, et al. CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance. Cancer Immunol Res. 2023;11:320-338 pubmed publisher |
| Xu Q, Milanez Almeida P, Martins A, Radtke A, Hoehn K, Oguz C, et al. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. Nat Immunol. 2023;24:186-199 pubmed publisher |
| Schnizer C, Andreas N, Vivas W, Kamradt T, Baier M, Kiehntopf M, et al. Persistent humoral and CD4+ TH cell immunity after mild SARS-COV-2 infection-The CoNAN long-term study. Front Immunol. 2022;13:1095129 pubmed publisher |
| Nogimori T, Suzuki K, Masuta Y, Washizaki A, Yagoto M, Ikeda M, et al. Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Front Immunol. 2022;13:1081047 pubmed publisher |
| Qiu C, Wang J, Zhu L, Cheng X, Xia B, Jin Y, et al. Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors. Front Bioeng Biotechnol. 2022;10:1027619 pubmed publisher |
| Menges D, Zens K, Ballouz T, Caduff N, Llanas Cornejo D, Aschmann H, et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nat Commun. 2022;13:4855 pubmed publisher |
| Gao Y, Cai C, Wullimann D, Niessl J, Rivera Ballesteros O, Chen P, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022;55:1732-1746.e5 pubmed publisher |
| Kilpel xe4 inen A, Jimenez Moyano E, Blanch Lombarte O, Ouchi D, Pe xf1 a R, Quirant Sánchez B, et al. Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Front Immunol. 2022;13:815041 pubmed publisher |
| Eiva M, Omran D, Chacon J, Powell D. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. Eur J Immunol. 2022;52:96-108 pubmed publisher |
| Chen M, Li Y, Wu Y, Xie S, Ma J, Yue J, et al. Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer. Cancers (Basel). 2021;13: pubmed publisher |
| Duhen R, Ballesteros Merino C, Frye A, Tran E, Rajamanickam V, Chang S, et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun. 2021;12:1047 pubmed publisher |
| Thieme C, Anft M, Paniskaki K, Blazquez Navarro A, Doevelaar A, Seibert F, et al. Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Rep Med. 2020;1:100092 pubmed publisher |
| Rodriguez Garcia A, Sharma P, Poussin M, Boesteanu A, Minutolo N, Gitto S, et al. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Mol Ther. 2020;28:548-560 pubmed publisher |
| Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, et al. ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. Front Immunol. 2017;8:1918 pubmed publisher |
| van de Sandt C, Kreijtz J, Geelhoed Mieras M, Nieuwkoop N, Spronken M, van de Vijver D, et al. Differential Recognition of Influenza A Viruses by M158-66 Epitope-Specific CD8+ T Cells Is Determined by Extraepitopic Amino Acid Residues. J Virol. 2016;90:1009-22 pubmed publisher |
| Hodge G, Hodge S, Reynolds P, Holmes M. Targeting peripheral blood pro-inflammatory CD28null T cells and natural killer T-like cells by inhibiting CD137 expression: possible relevance to treatment of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2013;32:1081-9 pubmed publisher |
| Afanasiev O, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer J, et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013;19:5351-60 pubmed publisher |
| Tischer S, Kaireit T, Figueiredo C, Hiller O, Maecker Kolhoff B, Geyeregger R, et al. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes. Int Immunol. 2012;24:561-72 pubmed publisher |
